var data={"title":"Cabozantinib: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Cabozantinib: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/529450?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=cabozantinib-patient-drug-information\" class=\"drug drug_patient\">see &quot;Cabozantinib: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15674859\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Perforations and fistulas (Cometriq):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">GI perforations occurred in 3% and fistula formation in 1% of cabozantinib-treated patients. Discontinue cabozantinib for perforation or for fistula formation.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hemorrhage (Cometriq):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Severe and sometimes fatal hemorrhage, including hemoptysis and GI hemorrhage, occurred in 3% of cabozantinib-treated patients. Monitor patients for signs and symptoms of bleeding. Do not administer cabozantinib to patients with severe hemorrhage.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16047819\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Cabometyx;</li>\n      <li>Cometriq</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15674860\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Tyrosine Kinase Inhibitor;</li>\n      <li>\n        Antineoplastic Agent, Vascular Endothelial Growth Factor (VEGF) Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15846538\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Do not substitute cabozantinib tablets and capsules. Cabozantinib is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea/vomiting (Hesketh 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Renal cell carcinoma, advanced: Cabometyx:</b> Oral: 60 mg once daily, continue as long as benefiting clinically or until unacceptable toxicity occurs (Choueiri 2015; Choueiri 2017); do not exceed 80 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Thyroid cancer, medullary, metastatic: Cometriq:</b> Oral: 140 mg once daily until disease progression or unacceptable toxicity occurs (Schlumberger 2017); do not exceed 180 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Missed doses:</i> Do not take a missed dose within 12 hours of the next dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosage adjustment for concomitant CYP3A4 inhibitors/inducers:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Strong CYP3A4 inhibitors:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cabometyx: Reduce the daily dose of cabozantinib by 20 mg (from 60 mg to 40 mg daily or from 40 mg to 20 mg daily). If the strong inhibitor is discontinued, allow ~2 to 3 days to elapse prior to adjusting the cabozantinib dose upwards to the dose used prior to the initiation of the strong inhibitor.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cometriq: Avoid concomitant use; if concomitant use is required, <b>reduce</b> the daily dose of cabozantinib by 40 mg (ie, from 140 mg to 100 mg daily or from 100 mg to 60 mg daily). If the strong inhibitor is discontinued, allow ~2 to 3 days to elapse prior to adjusting the cabozantinib dose upwards to the dose used prior to the initiation of the strong inhibitor.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Strong CYP3A4 inducers:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cabometyx: Increase the daily dose of cabozantinib by 20 mg (from 60 mg to 80 mg daily or from 40 mg to 60 mg daily) as tolerated; do not exceed 80 mg daily. If the strong inducer is discontinued, allow ~2 to 3 days to elapse prior to reducing the cabozantinib dose to the dose used prior to the initiation of the strong inducer.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cometriq: Avoid concomitant use; if concomitant use is required, <b>increase</b> the daily dose of cabozantinib by 40 mg (ie, from 140 mg to 180 mg daily or from 100 mg to 140 mg daily); do not exceed 180 mg. If the strong inducer is discontinued, allow ~2 to 3 days to elapse prior to reducing the cabozantinib dose to the dose used prior to the initiation of the strong inducer.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosage adjustment for surgery:</b> Withhold treatment for at least 28 days prior to scheduled surgery (including dental surgery). Resume therapy based on clinical judgment of adequate wound healing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15846558\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>The estimated glomerular filtration rate (eGFR) is estimated using MDRD (modification of diet in renal disease) equation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">eGFR &ge;30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup> or dialysis: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15846559\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild or moderate impairment (Child-Pugh classes A and B):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cabometyx: Reduce the initial dose to 40 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cometriq: Reduce the initial dose to 80 mg once daily. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe impairment (Child-Pugh class C): Use is not recommended (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15846539\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cabometyx:</b> Grade 3 or lower adverse reactions may require dosage reduction and/or supportive care (if a dose reduction is required, reduce dose by 20 mg from the prior dose).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Grade 4 adverse reactions or intolerable grade 3 or lower adverse reactions:</i> Withhold therapy. Upon return to baseline or improvement to grade 1, resume therapy with a reduction in dose. If previously receiving 60 mg daily, resume therapy at 40 mg daily. If previously receiving 40 mg daily, resume therapy at 20 mg daily. If previously receiving 20 mg daily, resume at 20 mg daily if tolerated; if not tolerated, discontinue therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Diarrhea (intolerable grade 2 or grade 3 or 4 that cannot be managed with standard antidiarrheal therapy):</i> Withhold therapy. Upon improvement to grade 1, resume at a reduced dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Hypertension (inadequately controlled with medical management):</i> Withhold therapy. When controlled, resume at a reduced dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Palmar-plantar erythrodysesthesia (Grade 3 or intolerable grade 2):</i> Withhold therapy. Upon improvement to grade 1, resume at a reduced dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Permanently discontinue for:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Development of unmanageable fistula or gastrointestinal perforation</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hypertensive crisis, severe uncontrolled hypertension despite optimal therapy</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Nephrotic syndrome</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Reversible posterior leukoencephalopathy syndrome (RPLS)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Serious arterial thromboembolic event (eg, MI or cerebral infarction)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cometriq:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Hematologic:</i> Withhold therapy for grade 4 hematologic adverse reactions. Upon return to baseline or improvement to grade 1, reduce the dose to 100 mg daily. If previously receiving 100 mg daily, resume therapy at 60 mg daily. If previously receiving 60 mg daily, resume at 60 mg daily if tolerated; otherwise, discontinue therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Other toxicity:</i> Withhold therapy for grade 3 or higher nonhematologic toxicity or intolerable grade 2 toxicity. Upon return to baseline or improvement to grade 1, reduce the dose to 100 mg daily. If previously receiving 100 mg daily, resume therapy at 60 mg daily. If previously receiving 60 mg daily, resume at 60 mg daily if tolerated; otherwise, discontinue therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Hypertension (inadequately controlled with medical management):</i> Withhold therapy. When controlled, resume at a reduced dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Palmar-plantar erythrodysesthesia (Grade 3 or intolerable grade 2): </i>Withhold therapy. Upon improvement to grade 1, resume at a reduced dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Permanently discontinue for:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Malignant hypertension, hypertensive crisis, persistent uncontrolled hypertension despite optimal therapy</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Nephrotic syndrome</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Osteonecrosis of the jaw</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Reversible posterior leukoencephalopathy syndrome (RPLS)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Serious arterial thromboembolic event (eg, MI or cerebral infarction)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Visceral perforation or fistula formation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16047820\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, oral [each package contains four blister cards; each card contains the following]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cometriq: 60 mg daily-dose: 20 mg (21s) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cometriq: 100 mg daily-dose: 80 mg (7s) and 20 mg (7s)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cometriq: 140 mg daily-dose: 80 mg (7s) and 20 mg (21s) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cabometyx: 20 mg, 40 mg, 60 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16058319\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;display:inline\">Contact Exelixus Access Services for information on obtaining cabozantinib (855-253-3273).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15846579\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Administer on an empty stomach (1 hour before or 2 hours after eating). <b>Note:</b> The prescribing information describes when to give food with respect to cabozantinib; no food should be consumed for at least 2 hours before or for at least 1 hour after the cabozantinib dose. Swallow whole; do not open capsules or crush tablets.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cabozantinib is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea/vomiting (Hesketh 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49104438\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]). </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15674862\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Renal cell carcinoma, advanced (Cabometyx):</b> Treatment of advanced renal cell carcinoma (RCC)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Thyroid cancer, medullary (Cometriq):</b> Treatment of progressive, metastatic medullary thyroid cancer (MTC)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15838145\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Cabozantinib may be confused with axitinib, bosutinib, cabazitaxel, ceritinib, cobimetinib, crizotinib, dasatinib, imatinib, nilotinib, regorafenib, ruxolitinib, vandetanib, vemurafenib</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Cabometyx may be confused with Cometriq</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Cabozantinib tablets (Cabometyx) and capsules (Cometriq) are NOT interchangeable; do not substitute.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15809126\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (33% to 61%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (41% to 56%), mouth pain (36%), voice disorder (20%), headache (11% to 18%), dizziness (11% to 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Palmar-plantar erythrodysesthesia (42% to 50%), hair discoloration (34%), skin rash (19% to 23%), xeroderma (11% to 19%), alopecia (16%), erythema (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Increased serum triglycerides (53%), hypocalcemia (52%), weight loss (31% to 48%), hypophosphatemia (28% to 48%), hyperglycemia (37%), hypoalbuminemia (36%), hypomagnesemia (19% to 31%), hyponatremia (10% to 30%), increased gamma-glutamyl transferase (27%), hypothyroidism (21%), hypokalemia (18%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (63% to 74%), stomatitis (22% to 51%), decreased appetite (46%), nausea (43% to 50%), dysgeusia (24% to 34%), abdominal pain (23% to 27%), constipation (25% to 27%), vomiting (24% to 32%), mucosal inflammation (19%), dysphagia (13%), dyspepsia (11% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Proteinuria (2% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Lymphocytopenia (53%; grades 3/4: 16%), neutropenia (35%; grades 3/4: 3%), thrombocytopenia (35%), anemia (17%; grades 3/4: 1% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum ALT (68% to 86%), increased serum AST (74% to 86%), increased serum alkaline phosphatase (35% to 52%), hyperbilirubinemia (25%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (19% to 21%), arthralgia (11% to 14%), limb pain (14%), muscle spasm (12% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased serum creatinine (58%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dyspnea (19%), cough (18%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Venous thromboembolism (4% to 9%), hypotension (7%), pulmonary embolism (5%), arterial thromboembolism (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Anxiety (9%), paresthesia (7%), peripheral sensory neuropathy (7%), peripheral neuropathy (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Hyperkeratosis (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Dehydration (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Hemorrhoids (9%), gastrointestinal perforation (&le;3%), gastrointestinal fistula (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Hemorrhage (&ge;grade 3: 2% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Musculoskeletal chest pain (9%), osteonecrosis of the jaw (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fistula (nongastrointestinal: 4%), wound healing impaired (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Cholestatic hepatitis, hypertensive crisis, pancreatitis, reversible posterior leukoencephalopathy syndrome, seizure</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15840645\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">There are no contraindications listed in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15840658\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatologic toxicity: Palmar-plantar erythrodysesthesia syndrome (PPES) was commonly observed in clinical trials; severe PPES (&ge; grade 3) also occurred frequently. May require dosage reduction and/or discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI toxicity: Diarrhea was commonly observed in cabozantinib-treated patients in clinical trials. May require therapy interruption and/or dosage reduction. Cabozantinib is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea/vomiting (Hesketh 2017). <b>[US Boxed Warning]: Cometriq: Serious GI perforations and fistulas have been reported when used for medullary thyroid cancer; discontinue for GI perforation or fistula formation.</b> May be fatal. Tracheal/esophageal fistulas were also noted; some cases were fatal. GI fistula/perforation (including fatal perforations) were also reported in patients with renal cell cancer. Monitor for signs/symptoms of perforations and fistulas, including abscess and sepsis. May require therapy discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hemorrhage: <b>[US Boxed Warning]: Cometriq: Serious and occasionally fatal hemorrhage (including hemoptysis and gastrointestinal) has occurred with cabozantinib when used for medullary thyroid cancer. Monitor for signs/symptoms of bleeding and do not administer to patients with severe hemorrhage</b> or a recent history of hemorrhage or hemoptysis. Severe hemorrhage has also been reported in patients with renal cell cancer, including grade 3 or higher events. Do not administer to patients with or at risk for severe hemorrhage.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypertension: Treatment emergent hypertension was commonly seen in clinical trials (including grade 3 or higher toxicity and hypertensive crisis). Monitor blood pressure prior to therapy initiation and regularly thereafter; withhold for hypertension that is uncontrolled with appropriate medical management. May require cabozantinib dosage reduction and/or therapy discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Osteonecrosis of the jaw: Osteonecrosis of the jaw (ONJ) occurred rarely; oral examinations should be performed prior to and periodically throughout therapy. Patients should maintain proper oral hygiene practices; if possible, withhold therapy for at least 28 days prior to scheduled invasive dental procedures. Discontinue cabozantinib if ONJ develops.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Proteinuria: Proteinuria occurred in a small number of patients receiving cabozantinib in clinical trials; nephrotic syndrome was also reported (rare). Monitor urine protein regularly and discontinue therapy if nephrotic syndrome develops.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Reversible posterior leukoencephalopathy syndrome: Reversible posterior leukoencephalopathy syndrome (RPLS), also referred to as posterior reversible leukoencephalopathy syndrome (PRES), occurred rarely in clinical studies. Monitor for signs/symptoms of RPLS (seizures, headache, visual disturbances, confusion or altered mental function); if diagnosis confirmed, discontinue therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thromboembolic events: An increased incidence of thrombotic events (venous thromboembolism, including pulmonary embolism and arterial thromboembolism) was seen in cabozantinib-treated patients in clinical trials; discontinue therapy in patients who develop an acute myocardial infarction, cerebral infarction, or other clinically significant arterial thromboembolic event.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Wound healing impairment: Cabozantinib inhibits vascular endothelial growth factor receptors 1, 2, and 3; wound complications have been reported with therapy. Hold treatment at least 28 days prior to scheduled surgery (including dental surgery); resume based on judgment of adequate wound healing post surgery. Withhold treatment in patients with dehiscence or other wound healing complications requiring intervention.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Cabozantinib exposure is increased in patients with hepatic impairment. Reduced initial doses are recommended for patients with mild or moderate impairment; use is not recommended in patients with severe impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Formulations: Cabozantinib is available in tablets (Cabometyx) and capsules (Cometriq) which are NOT interchangeable; do NOT substitute.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16061023\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2C9 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16061021\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=87299&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bisphosphonate Derivatives: Angiogenesis Inhibitors (Systemic) may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Specifically, the risk for osteonecrosis of the jaw may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of Cabozantinib. Management: Avoid use of strong CYP3A4 inducers with cabozantinib if possible. If combined, cabozantinib dose adjustments are recommended and vary based on the cabozantinib product used and the indication for use. See monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Cabozantinib. Management: Avoid use of a strong CYP3A4 inhibitor with cabozantinib if possible. If combined, cabozantinib dose adjustments are recommended and vary based on the cabozantinib product used and the indication for use. See monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grapefruit Juice: May increase the serum concentration of Cabozantinib.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MRP2 Inhibitors: May increase the serum concentration of Cabozantinib.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifapentine: May decrease the serum concentration of Cabozantinib.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of Cabozantinib.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15846439\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">A high-fat meal increased C<sub>max</sub> and AUC by 41% and 57%, respectively compared to the fasted state. Cabozantinib serum concentrations may be increased when taken with grapefruit or grapefruit juice. Management: Must be taken on an empty stomach, at least 1 hour before and 2 hours after food. Avoid concurrent use with grapefruit or grapefruit juice.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15840642\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Based on its mechanism of action, adverse effects on pregnancy would be expected. Patients (male and female) should use effective contraception during therapy and for 4 months after therapy completion. Cabozantinib may impair fertility in females and males.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15840644\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if cabozantinib is present in breast milk. Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends discontinuing breastfeeding during treatment and for 4 months after the last dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15846578\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Avoid grapefruit and grapefruit juice throughout therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15846581\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Renal function, liver function, CBC with differential and platelets, serum electrolytes; blood pressure (prior to initiation and regularly during therapy); monitor for perforations, fistulas, signs/symptoms of bleeding, palmar-plantar erythrodysesthesia syndrome (PPES), reversible posterior leukoencephalopathy syndrome (RPLS), proteinuria (regularly during therapy), osteonecrosis of the jaw (perform oral examination prior to initiation and periodically during therapy), wound healing complications, diarrhea, stomatitis. Monitor adherence.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15846442\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Cabozantinib is a potent inhibitor of proinvasive receptor tyrosine kinases (RTKs), including AXL, FLT-3, KIT, MER, MET, RET, ROS1, TIE-2, TRKB, TYRO3, and VEGFR-1, -2, and -3; induces apoptosis of cancer cells and suppresses tumor growth, metastasis, and angiogenesis (Yakes 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15846444\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: ~319 to 349 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Following a single 140 mg dose, a 19% increase in the C<sub>max</sub> was observed with the tablet (compared to the capsule), although the difference in AUC was &lt;10%.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: &ge;99.7% to plasma proteins</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic via CYP3A4</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: ~55 hours (Cometriq); ~99 hours (Cabometyx)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: 2 to 5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces (~54%; 43% as unchanged drug); urine (~27%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16570462\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Cometriq (100 mg Daily Dose) Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 X 80 &amp; 1 X 20 mg (56): $17,746.61</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Cometriq (140 mg Daily Dose) Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 X 80 &amp; 3 X 20 mg (112): $17,746.61</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Cometriq (60 mg Daily Dose) Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (84): $17,746.61</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Cabometyx Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (30): $19,100.82</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (30): $19,100.82</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (30): $19,100.82</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F30134486\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Cabometyx (AU, GB, KR);</li>\n      <li>Cometriq (AT, BB, CZ, DE, DK, EE, ES, FI, FR, GB, HR, HU, IE, IS, LT, MT, NL, NO, PL, PT, SE, SK);</li>\n      <li>Kabometics (KR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Cabometyx (cabozantinib) [prescribing information]. South San Francisco, CA: Exelixis, Inc; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. <i>N Engl J Med</i>. 2015;373(19):1814-1823.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cabozantinib-drug-information/abstract-text/26406150/pubmed\" target=\"_blank\" id=\"26406150\">26406150</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. <i>J Clin Oncol</i>. 2017;35(6):591-597. doi: 10.1200/JCO.2016.70.7398.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cabozantinib-drug-information/abstract-text/28199818/pubmed\" target=\"_blank\" id=\"28199818\">28199818</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cometriq (cabozantinib) [prescribing information]. South San Francisco, CA: Exelixis Inc; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Durante C, Russo D, Verrienti A, et al, &ldquo;XL184 (Cabozantinib) for Medullary Thyroid Carcinoma,&rdquo; <i>Expert Opin Investig Drugs</i>, 2011, 20(3):407-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cabozantinib-drug-information/abstract-text/21314233/pubmed\" target=\"_blank\" id=\"21314233\">21314233</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. <i>J Clin Oncol</i>. 2017;35(28):3240-3261. doi: 10.1200/JCO.2017.74.4789.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cabozantinib-drug-information/abstract-text/28759346/pubmed\" target=\"_blank\" id=\"28759346\">28759346</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kurzrock R, Sherman SI, Ball DW, et al, &ldquo;Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer,&rdquo; <i>J Clin Oncol</i>, 2011, 29(19):2660-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cabozantinib-drug-information/abstract-text/21606412/pubmed\" target=\"_blank\" id=\"21606412\">21606412</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schlumberger M, Elisei R, M&uuml;ller S, et al. Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma. <i>Ann Oncol</i>. 2017;28(11):2813-2819. doi: 10.1093/annonc/mdx479.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cabozantinib-drug-information/abstract-text/29045520/pubmed\" target=\"_blank\" id=\"29045520\">29045520</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith DC, Smith MR, Sweeney C, et al, &ldquo;Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial,&rdquo; <i>J Clin Oncol</i>, 2013, 31(4):412-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cabozantinib-drug-information/abstract-text/23169517/pubmed\" target=\"_blank\" id=\"23169517\">23169517</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yakes FM, Chen J, Tan J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. <i>Mol Cancer Ther.</i> 2011;10(12):2298-2308.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cabozantinib-drug-information/abstract-text/21926191/pubmed\" target=\"_blank\" id=\"21926191\">21926191</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 87299 Version 115.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F15674859\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F16047819\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F15674860\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F15846538\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15846558\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15846559\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F15846539\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F16047820\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F16058319\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F15846579\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49104438\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F15674862\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F15838145\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F15809126\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F15840645\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F15840658\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F16061023\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F16061021\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F15846439\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F15840642\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F15840644\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F15846578\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F15846581\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F15846442\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F15846444\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16570462\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F30134486\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/87299|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=cabozantinib-patient-drug-information\" class=\"drug drug_patient\">Cabozantinib: Patient drug information</a></li></ul></div></div>","javascript":null}